What’s new

• FY26 revenue rose 10.8% to ₹141.5 cr; net profit up 15.5% to ₹5.5 cr.
• ₹30 cr atrazine expansion is targeted to add ₹120-140 cr in annual revenue.
• Management detailed a compressed biogas and biomass pellet project with combined capex over ₹250 cr.

Why it matters

The renewable capex is more than 45 times FY26 profit. For a company making ₹5.5 crore a year, this is a transformative bet on future cash flows.

What we’re watching

• Funding plan and timeline for the ₹250 cr-plus renewable capex.
• Atrazine capacity ramp versus the ₹120-140 cr revenue target.
• Execution against the 20% FY27 consolidated growth guidance.

The full read

Dhansa Labs closed FY26 with ₹141.5 crore in revenue and ₹5.5 crore in net profit. The results are secondary to what management laid out for the year ahead. A ₹30 crore atrazine capacity build is expected to deliver ₹120-140 crore in annual revenue once stabilized. The renewable energy push is bigger. Two projects, a compressed biogas plant and a biomass pellet facility, will together cost more than ₹250 crore. That sum is more than 45 times FY26 profit. The 20% FY27 growth guidance ties these threads together. The capital commitment is the main story. The open question is how Dhansa, with its current balance sheet, funds this expansion while delivering on operational targets.

Primary source: NSE